Differential growth and responsiveness to cancer therapy of tumor cells in different environments

Area of Science:

• Oncology
• Cancer Metastasis Research
• Translational Medicine

Background:

• Tumor metastasis is a major cause of cancer mortality.
• Current therapies often fail due to the assumption that metastatic tumors are uniform across different organs.
• There is a need to understand the biological differences of tumors in diverse microenvironments.

Purpose of the Study:

• To investigate the hypothesis that tumors exhibit biological heterogeneity in growth potential and therapeutic response across different organs.
• To establish a reliable model for studying multi-organ tumor growth and response.
• To highlight the importance of organ-specific differences in metastatic tumor behavior.

Main Methods:

• Development of a multi-organ tumor growth model in mice using hydrodynamic cell delivery.
• Simultaneous establishment of quantifiable tumor growth in the liver, lungs, and kidneys.
• Assessment of tumor growth rates and response to chemotherapy (dacarbazine) and immune gene therapy (interferon beta gene).

Main Results:

• Melanoma tumor growth rate was significantly higher in the liver compared to the lungs and kidneys.
• Tumors in the lungs and kidneys showed initial minimal growth followed by aggressive proliferation.
• Differential responses to chemotherapy and gene therapy were observed across organs; lung tumors responded better to chemotherapy, while liver and kidney tumors showed better response to interferon beta gene therapy.

Conclusions:

• Metastatic tumors demonstrate significant biological heterogeneity in growth and response to therapy based on their organ environment.
• The findings underscore the inadequacy of current therapeutic strategies that do not account for organ-specific tumor characteristics.
• New drug screening strategies must incorporate the environmental differences at metastatic sites to improve treatment efficacy for cancer patients.